MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Viatris Depreciation & Amortization 2011-2026 | VTRS
Annual Depreciation & Amortization Viatris
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.03 B | 4.51 B | 2.22 B | 2.02 B | 2.11 B | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.51 B | 2.02 B | 2.78 B |
Quarterly Depreciation & Amortization Viatris
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 593 M | 583 M | 665 M | 575 M | 597 M | 691 M | 584 M | 591 M | 730 M | - | 2.16 B | 634 M | 736 M | - | 3.76 B | 2.74 B | 1.42 B | - | 1.26 B | 831 M | 415 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.76 B | 415 M | 1.09 B |
Depreciation & Amortization of other stocks in the Drug manufacturers industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
8.75 M | - | - | $ 142 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
1.48 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
6.4 M | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
21.5 M | $ 1.28 | 7.8 % | $ 138 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
311 K | - | 7.5 % | $ 6.35 M | USA |
 |
Agile Therapeutics
AGRX
|
102 K | - | 10.11 % | $ 58.2 M | USA |
 |
Catalent
CTLT
|
489 M | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
31 K | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
646 K | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
306 M | - | - | $ 28.9 M |  Irlanda |
 |
Emergent BioSolutions
EBS
|
125 M | $ 13.4 | -3.67 % | $ 686 M | USA |
 |
Athenex
ATNX
|
4.47 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
2.68 M | $ 21.48 | -0.09 % | $ 2.04 B |  France |
 |
Evolus
EOLS
|
5.3 M | $ 5.72 | 0.97 % | $ 355 M | USA |
 |
Harrow Health
HROW
|
1.06 M | $ 50.59 | -0.81 % | $ 1.65 B | USA |
 |
China Pharma Holdings
CPHI
|
2.62 M | $ 1.39 | 2.21 % | $ 24.3 M |  China |
 |
Jupiter Wellness
JUPW
|
429 K | - | - | $ 33.6 M | USA |
 |
Bausch Health Companies
BHC
|
1.26 B | $ 7.81 | -1.2 % | $ 2.85 B | Canada |
 |
Lannett Company
LCI
|
34.3 M | - | 1.15 % | $ 7.11 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
4.9 M | $ 4.78 | -7.96 % | $ 67.2 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
3.26 M | - | - | $ 193 M | Canada |
 |
Organogenesis Holdings
ORGO
|
13.6 M | $ 4.25 | -1.28 % | $ 560 M | USA |
 |
Pacira BioSciences
PCRX
|
78.8 M | $ 26.09 | 0.35 % | $ 1.21 B | USA |
 |
PetIQ
PETQ
|
44.5 M | - | 1.64 % | $ 400 M | USA |
 |
Perrigo Company plc
PRGO
|
326 M | $ 14.84 | 1.64 % | $ 2.04 B | USA |
 |
ProPhase Labs
PRPH
|
4.72 M | - | - | $ 5.07 M | USA |
 |
Recro Pharma
REPH
|
8.22 M | - | -4.76 % | $ 65.3 M | USA |
 |
Radius Health
RDUS
|
1.16 M | - | - | $ 1.42 B | USA |
 |
Rockwell Medical
RMTI
|
1.44 M | $ 1.0 | 4.65 % | $ 23.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
1.26 K | $ 4.4 | 1.85 % | $ 132 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
138 K | $ 3.82 | 1.33 % | $ 4.74 M | USA |
 |
OptiNose
OPTN
|
402 K | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
28.2 M | $ 9.4 | -0.32 % | $ 668 M | USA |
 |
PLx Pharma
PLXP
|
116 K | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
2.46 M | $ 5.32 | -5.17 % | $ 217 M | USA |
 |
Tilray
TLRY
|
35.7 M | $ 9.13 | 1.57 % | $ 5.64 B | Canada |
 |
SCYNEXIS
SCYX
|
580 K | $ 0.67 | 3.96 % | $ 32.1 M | USA |
 |
Tricida
TCDA
|
442 K | - | - | $ 3.25 M | USA |
 |
Veru
VERU
|
268 K | $ 2.32 | -2.11 % | $ 313 M | USA |
 |
TherapeuticsMD
TXMD
|
922 K | $ 2.01 | -1.62 % | $ 21 M | USA |
 |
cbdMD
YCBD
|
452 K | $ 1.1 | - | $ 4.74 M | USA |
 |
Zomedica Corp.
ZOM
|
830 K | - | -0.21 % | $ 98 M | USA |